Prostate Cancer News on BioPortfolio

Biological markers that could guide treatment for prostate cancer

Genetic alterations in lowrisk prostate cancer diagnosed by needle biopsy can identify men that harbor higherrisk cancer in their prostate glands researchers have discovered. The research found for the first time that genetic alterations associated with in...

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer. Filed for IPO $HARP httpswww.businesswire.comnewshome20190102005182enHarpoonTherapeuticsAnnouncesPreliminarySafetyPharm

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer. Filed for IPO $HARP httpswww.businesswire.comnewshome20190102005182enHarpoonTherapeuticsAnnouncesPreliminarySafetyPharmacologyData ...

Quick Take Shortterm androgen suppression and radiotherapy versus intermediateterm androgen suppression and radiotherapy with or without zoledronic acid in men with locally advanced prostate cancer TROG 03.04 RADAR 10year results from a randomise

The optimal duration of androgen suppression therapy with radiotherapy for locally advanced prostate cancer is unknown. In 2018 the French Canadian Prostate Cancer Study PCS IV trial showed that 18 months of androgen suppression and radiotherapy is associa...

Pages